Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleCannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.
Author(s)Vicente-Valor MI, Garcia-Llopis P, Mejia Andujar L, Antonino de la Camara G, García Del Busto N, Lopez Tinoco M, Quintana Vergara B, Peiro Vilaplana C, Dominguez Moran JA, Sánchez Alcaraz A.
Journal, Volume, IssueJ Clin Pharm Ther. 2012 Jun 21. doi: 10.1111/j.1365-2710.2012.01365.x. [Epub ahead of print]
Major outcome(s)The cannabis extract was effective in a patient with stiff person syndrome.
IndicationPain;SpasticityAbstract
MedicationCannabis

What is known and objective:  Stiff-person syndrome (SPS) is an uncommon and
disabling disorder characterized by progressive rigidity and episodic painful
spasms involving axial and limb musculature. SPS treatment is mostly based on
benzodiazepines, baclofen, immunosuppressants and intravenous immunoglobulin.
Cannabis derivatives [tetrahydrocannabinol (THC) and cannabidiol (CBD)] are
available as an oromucosal spray (Sativex(®) ), indicated as add-on treatment,
for symptom improvement in patients with moderate to severe spasticity because of
multiple sclerosis (MS). Our objective is to report a case of seronegative SPS
successfully treated with THC-CBD oromucosal spray. Case summary:  We report a
case of a 40-year-old man presenting with progressive muscle stiffness and
intermittent spasms for 6-years. The diagnosis of stiff-person syndrome was based
on the clinical features and neuroelectrophysiologic findings of continuous motor
unit activity. Glutamic acid decarboxylase autoantibodies was absent in our
patient, in both serum and cerebrospinal fluid (CSF). Cannabis derivatives
oromucosal spray was introduced after a series of unsatisfactory traditional
medical treatments. After 14 months treated with THC-CBD oromucosal spray,
improvement was verified in the eight dimensions of the scale of SF-36 quality of
life questionnaire. What is new and conclusion:  Clinical experience with
cannabis derivatives in patients with multiple sclerosis is accumulating
steadily, but there is no current literature about its efficacy for SPS. Because
MS and SPS share some neurological symptoms such as spasticity and rigidity, it
is thought that THC-CBC can be an option for SPS patient. Our case report
suggests that THC-CBD oromucosal spray is an alternative treatment for patients
with refractory SPS, and further validation is appropriate.

Route(s)Sublingual
Dose(s)
Duration (days)
Participants1 patient with stiff person syndrome
DesignUncontrolled case report
Type of publicationMedical journal
Address of author(s)Pharmacy Department Neurology Department, Hospital Universitario de la Ribera, Alzira, Valencia, España.
Full text

[Back to Overview]  [IACM Homepage]


up